Context Identifying the most effective first-line treatment for metastatic renal cell carcinoma
(mRCC) is challenging as rapidly evolving data quickly outdate the existing body of …

Background The efficacy and safety of nivolumab plus cabozantinib as compared with those
of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not …

Although decision making strategy based on clinico-histopathological criteria is well
established, renal cell carcinoma (RCC) represents a spectrum of biological ecosystems …

Background No trials have compared cabozantinib and regorafenib for the second-line
treatment of advanced hepatocellular carcinoma (HCC). Objectives Conduct a matching …

Background Since the approval of tyrosine kinase inhibitors, angiogenesis inhibitors and
immune checkpoint inhibitors, the treatment landscape for advanced renal cell carcinoma …

The treatment of metastatic clear-cell renal cell cancer (mccRCC) has seen substantial
progress over the last decade. Until 2006, non-specific immunotherapy with high dose …

Oral cabozantinib tablets (Cabometyx®) are an important option for the treatment of
advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and …

The treatment landscape for metastatic renal cell carcinoma (mRCC) has undergone a
substantial evolution in the past decade, with a dramatic increase in the number of available …

Simple Summary ICI-based combinations have led to a significant change in mRCC medical
treatment. However, data from real-world (RW) cohorts are rare. In this multicenter study, we …

Background In the past few years, new drugs made their appearance in the first-line setting
of treatment for metastatic renal cell carcinoma (mRCC), and cabozantinib is one among …